Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics has reported Accumulated Expenses over the past 7 years, most recently at $5.7 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $5.7 million for Q1 2026, up 42.88% from a year ago — trailing twelve months through Mar 2026 was $5.7 million (up 42.88% YoY), and the annual figure for FY2025 was $12.4 million, up 23.61%.
  • Accumulated Expenses reached $5.7 million in Q1 2026 per EWTX's latest filing, down from $12.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.4 million in Q4 2025 and bottomed at $2.1 million in Q1 2023.
  • Median Accumulated Expenses over the past 5 years was $5.6 million (2025), compared with a mean of $5.6 million.
  • The largest annual shift saw Accumulated Expenses soared 210.27% in 2022 before it plummeted 37.49% in 2023.
  • Over 5 years, Accumulated Expenses stood at $4.0 million in 2022, then soared by 41.25% to $5.7 million in 2023, then soared by 76.58% to $10.1 million in 2024, then rose by 23.61% to $12.4 million in 2025, then tumbled by 54.32% to $5.7 million in 2026.
  • Business Quant data shows Accumulated Expenses for EWTX at $5.7 million in Q1 2026, $12.4 million in Q4 2025, and $8.0 million in Q3 2025.